361 related articles for article (PubMed ID: 24666181)
1. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients.
Ismaila A; Corriveau D; Vaillancourt J; Parsons D; Dalal A; Su Z; Sampalis JS
Curr Med Res Opin; 2014 Jul; 30(7):1427-36. PubMed ID: 24666181
[TBL] [Abstract][Full Text] [Related]
2. Impact of adherence to treatment with fluticasone propionate/salmeterol in asthma patients.
Ismaila A; Corriveau D; Vaillancourt J; Parsons D; Stanford R; Su Z; Sampalis JS
Curr Med Res Opin; 2014 Jul; 30(7):1417-25. PubMed ID: 24666139
[TBL] [Abstract][Full Text] [Related]
3. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease.
Chatterjee A; Shah M; D'Souza AO; Bechtel B; Crater G; Dalal AA
Respir Res; 2012 Feb; 13(1):15. PubMed ID: 22340019
[TBL] [Abstract][Full Text] [Related]
4. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
Dalal AA; Candrilli SD; Davis KL
Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.
Roberts MH; Dalal AA
Int J Chron Obstruct Pulmon Dis; 2012; 7():221-33. PubMed ID: 22500122
[TBL] [Abstract][Full Text] [Related]
7. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
Roberts M; Mapel D; Petersen H; Blanchette C; Ramachandran S
J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
Jung KS; Park HY; Park SY; Kim SK; Kim YK; Shim JJ; Moon HS; Lee KH; Yoo JH; Lee SD; ;
Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
[TBL] [Abstract][Full Text] [Related]
10. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies.
Delea TE; Hagiwara M; Dalal AA; Stanford RH; Blanchette CM
Curr Med Res Opin; 2009 Jan; 25(1):1-13. PubMed ID: 19210134
[TBL] [Abstract][Full Text] [Related]
11. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
Hanania NA; Crater GD; Morris AN; Emmett AH; O'Dell DM; Niewoehner DE
Respir Med; 2012 Jan; 106(1):91-101. PubMed ID: 22040533
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care.
Bell CF; Coutinho AD; Farrelly E; Lokhandwala T; Landsman-Blumberg P
J Med Econ; 2018 Jun; 21(6):629-638. PubMed ID: 29577787
[TBL] [Abstract][Full Text] [Related]
13. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
14. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
Aaron SD; Vandemheen KL; Fergusson D; Maltais F; Bourbeau J; Goldstein R; Balter M; O'Donnell D; McIvor A; Sharma S; Bishop G; Anthony J; Cowie R; Field S; Hirsch A; Hernandez P; Rivington R; Road J; Hoffstein V; Hodder R; Marciniuk D; McCormack D; Fox G; Cox G; Prins HB; Ford G; Bleskie D; Doucette S; Mayers I; Chapman K; Zamel N; FitzGerald M;
Ann Intern Med; 2007 Apr; 146(8):545-55. PubMed ID: 17310045
[TBL] [Abstract][Full Text] [Related]
15. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
Cazzola M; Andò F; Santus P; Ruggeri P; Di Marco F; Sanduzzi A; D'Amato M
Pulm Pharmacol Ther; 2007; 20(5):556-61. PubMed ID: 16914336
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population.
Dalal AA; Shah M; D'Souza AO; Chaudhari S; Crater G
Int J Chron Obstruct Pulmon Dis; 2012; 7():11-9. PubMed ID: 22315518
[TBL] [Abstract][Full Text] [Related]
17. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
Delea TE; Hagiwara M; Stanford RH; Stempel DA
Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
[TBL] [Abstract][Full Text] [Related]
18. Is salmeterol/fluticasone propionate equivalent to tiotropium bromide in the treatment of COPD?
Gillissen A
Am J Respir Crit Care Med; 2008 Jul; 178(1):105; author reply 106-7. PubMed ID: 18565963
[No Abstract] [Full Text] [Related]
19. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis.
Liu Y; Shi H; Sun X; Zhang D; Zhang Y; Yang K; Mi L; Li M
Eur J Intern Med; 2014 Jun; 25(5):491-5. PubMed ID: 24816076
[TBL] [Abstract][Full Text] [Related]
20. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.
Frith PA; Thompson PJ; Ratnavadivel R; Chang CL; Bremner P; Day P; Frenzel C; Kurstjens N;
Thorax; 2015 Jun; 70(6):519-27. PubMed ID: 25841237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
